New prostate cancer drug tested in chinese men – early safety check

NCT ID NCT07339267

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called ASP5541 in Chinese men with advanced prostate cancer. The drug is given as a shot in the hip, along with standard treatments prednisone and hormone therapy. The main goals are to check the drug's safety and how it is processed by the body. About 12 men will take part, and they will continue treatment until their cancer worsens or their doctor decides to stop.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER METASTATIC HORMONE SENSITIVE PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.